Odyssey Therapeutics, Inc.
Research Odyssey Therapeutics, Inc. (ODTX) on Bullrun: market cap USD 874.50M. Explore financials, valuation history, model signals, and stock context.
Key Metrics
- TickerODTX
- ExchangeNASDAQ
- CountryUnited States
- SectorHealthcare
- IndustryBiotechnology
- CurrencyUSD
- Market capUSD 874.50M
- Financial periodQ2 2026
- RevenueUSD 0
- Net income-USD 52.79M
- Free cash flow-USD 34.69M
Valuation Snapshot
latest market cap is USD 874.50M.
Five-year financial history
| Year | Revenue | Net income | Free cash flow | Gross margin | Diluted EPS | Cash | Total debt | Equity |
|---|---|---|---|---|---|---|---|---|
| FY2025 | USD 2.98M | -USD 148.65M | -USD 130.70M | n/a | -5.39 | USD 41.69M | USD 27.11M | -USD 488.28M |
| FY2024 | USD 4.47M | -USD 129.32M | -USD 118.24M | n/a | -4.73 | USD 59.14M | USD 31.01M | -USD 382.53M |
| FY2023 | USD 1.04M | -USD 125.94M | -USD 117.78M | n/a | -1.32 | USD 52.55M | USD 34.38M | -USD 262.71M |
| FY2022 | USD 0 | -USD 124.67M | -USD 112.87M | n/a | -4.52 | USD 241.04M | USD 42.49M | -USD 144.62M |
Valuation history
| Year | Snapshot date | Market cap | P/E | Dividend yield | Annual dividend/share |
|---|---|---|---|---|---|
| 2026 | 2026-10-12 | USD 874.50M | n/a | n/a | n/a |
About Odyssey Therapeutics, Inc.
Odyssey Therapeutics, Inc., a clinical-stage biopharmaceutical company, develops medicines for autoimmune and inflammatory diseases. The company pipeline includes OD-001, an oral small molecule inhibitor of receptor-interacting protein kinase 2, which is in phase 2a trial for the treatment of ulcerative colitis; OD-002, an oral small molecule SLC15A4 inhibitor designed to block TLR7/8/9-mediated pathogenic inflammatory responses activation of interferon regulatory factor 5 (IRF5);
Related stock research
Other Healthcare stocks
Frequently asked questions
What is Odyssey Therapeutics, Inc.'s market cap?
Odyssey Therapeutics, Inc.'s market capitalization is USD 874.50M.
What does Odyssey Therapeutics, Inc. do?
Odyssey Therapeutics, Inc., a clinical-stage biopharmaceutical company, develops medicines for autoimmune and inflammatory diseases.